Ovid Therapeutics Inc 最大收入来源是 Novel Therapeutics,在最近的收益报告中收入为 391,695。就地区而言, United States 是 Ovid Therapeutics Inc 的主要市场,收入为 391,695。
Dividend 15 Split Corp II 是否盈利?
不,根据最新的财务报表,Ovid Therapeutics Inc 的净损失为 $-26
Dividend 15 Split Corp II 有负债吗?
是的,Ovid Therapeutics Inc 的负债为 23
Dividend 15 Split Corp II 的流通股有多少?
Ovid Therapeutics Inc 的总流通股为 71
关键数据
前收盘价
$5.47
开盘价
$5.82
当日区间
$5.47 - $5.82
52周范围
$3.24 - $5.82
交易量
100
平均成交量
160
股息收益率
--
每股收益(TTM)
1.93
市值
$147.5M
什么是 DIVIDEND 15 SPLIT CORP II?
Dividend 15 Split Corp II is a CA-based company operating in industry. The company is headquartered in Toronto, Ontario. The company went IPO on 2006-11-16. Dividend 15 Split Corp. II is a mutual fund. The firm invests in a portfolio of 15 dividend-yielding, Canadian companies. The investment objectives with respect to the Preferred shares are to provide holders of the Preferred shares with fixed, cumulative preferential monthly cash dividends in the amount of $0.05833 per Preferred share to yield 7.00% per annum based upon the original issue price of the Preferred Shares and to pay the holders $10 per Preferred share. The investment objectives with respect to the Class A Shares are to provide holders of Class A Shares with regular monthly cash dividends targeted to be $0.10 per Class A Share and to pay holders of Class A Shares $15.00 per Class A Share. The net asset value per unit must remain above the required $15 per unit threshold for distributions to be declared. The investment manager of the Company is Quadravest Capital Management Inc.